Lutropin Alfa Dosage
Applies to the following strengths: 75 intl units
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Follicle Stimulation
75 international units subcutaneously once a day
-This drug should be administered simultaneously with follitropin alpha injection (75 to 150 international units per day).
-Treatment should be tailored to the individual patient as assessed by measuring follicle size by ultrasound and estrogen response.
-Treatment can begin at any time and should not normally exceed 14 days unless signs of imminent follicular development are present; it may be acceptable to extend the duration of stimulation in any 1 cycle up to 5 weeks.
-Human chorionic gonadotropin (hCG) should be given 1 day after the last dose of lutropin alfa and follitropin alpha to complete follicular development and effect ovulation; precautions should be followed regarding ovarian hyperstimulation syndrome.
Use: For stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound leutinizing hormone (LH) deficiency (LH less than 1.2 international units/L).
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
-Hypersensitivity to the active substance or any product excipients
-Uncontrolled thyroid or adrenal failure
-Active, untreated tumors of the hypothalamus and pituitary gland
-Pregnancy and Lactation
-Ovarian, uterine, or mammary carcinoma
-Ovarian enlargement or ovarian cyst unrelated to polycystic ovarian disease and of unknown origin
-Abnormal uterine bleeding of unknown origin
This drug must not be used when a condition exists which would make a normal pregnancy impossible, such as:
-Primary ovarian failure
-Malformations of sexual organs incompatible with pregnancy
-Fibroid tumors of the uterus incompatible with pregnancy
Safety and efficacy have not been established in pediatric patients.
Consult WARNINGS section for additional precautions.
Data not available
-Administer subcutaneously once a day with follitropin alpha
-Patients should be instructed on self-administration
Missed Dose: If a dose is missed, patient should be instructed to contact her doctor
-Pre-filled Pens: Store in refrigerator (2C to 8C); do not freeze; protect from light
-Pre-filled Pens (In-use): Store refrigerated for up to 28 days after opening; discard unused portion
-Lyophilized vials: Store at 2C to 25C; protect from light
-Lyophilized powder for reconstitution: dissolve contents with supplied sterile water for injection; may be mixed in same syringe with Gonal-F lyophilized powder and given in one injection; mix gently, do not shake
-This drug is to be administered concomitantly with follitropin alpha; the safety and effectiveness of concomitant administration with other recombinant human FSH are unknown.
-A definitive effect on pregnancy in this population has not been demonstrated.
-Women with a history of tubal disease are at increased risk for ectopic pregnancy whether they conceive spontaneously or with fertility treatments; however, the prevalence of ectopic pregnancy after assistive reproductive technology is higher than in the general population.
-Monitor follicular development by ultrasound alone or in combination with serum estradiol levels
-Instruct patient to read the approved patient labeling.
-Patients should understand the duration of treatment and monitoring that will be required.
-Patients should understand their risk of ovarian hyperstimulation syndrome.
-Patients should understand their risk of multiple births.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.